Praxis Precision Medicines (PRAX) vs Protagonist Therapeutics (PTGX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Praxis Precision Medicines (PRAX) has outperformed Protagonist Therapeutics (PTGX) over the past year, gaining 434.2% versus a gain of 115.2%. Over five years, PTGX leads with a +355.0% price change compared with -7.4% for PRAX. Protagonist Therapeutics is the larger company by market cap ($9.14 billion vs $7.42 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PRAX | PTGX |
|---|---|---|
| Share price | $265.66 | $141.21 |
| Market cap | $7.42B | $9.14B |
| 1-day change | -4.45% | +0.20% |
| YTD return | -5.67% | +61.35% |
| 1-year return | +434.24% | +115.24% |
| 5-year return | -7.37% | +355.02% |
| P/E ratio (TTM) | — | 137.09 |
| EPS (TTM) | $-12.95 | $1.03 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | $46.02M |
| Revenue growth (YoY) | -100.00% | -89.41% |
| Net income (latest FY) | $-303.27M | $-130.15M |
| Operating margin | — | -343.63% |
| Net margin | — | -282.83% |
| 52-week high | $392.70 | $160.81 |
| 52-week low | $50.56 | $65.56 |
| Distance from 52-week high | -32.35% | -12.19% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +142.58% | +23.71% |
| Average volume | 403.18K | 632.64K |
| Shares outstanding | 27.92M | 64.71M |
| Employees | 168 | 141 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PRAX has outperformed PTGX by 319.0 percentage points over the past year.
- Protagonist Therapeutics grew revenue faster in its latest fiscal year (-89.41% vs -100.00%).
About Praxis Precision Medicines
PRAX stock →Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide.
Health Care · Biotechnology: Pharmaceutical Preparations · 168 employees
About Protagonist Therapeutics
PTGX stock →Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 141 employees
PRAX vs PTGX FAQ
Which is bigger, Praxis Precision Medicines or Protagonist Therapeutics?
Protagonist Therapeutics (PTGX) is larger, with a market capitalization of $9.14B compared with $7.42B for Praxis Precision Medicines (PRAX).
Which stock has performed better over the past year, PRAX or PTGX?
PRAX returned +434.24% over the past 12 months, compared with +115.24% for PTGX (price return, excluding dividends). Past performance does not predict future results.
Are Praxis Precision Medicines and Protagonist Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.